Biogen Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Biogen Inc.
Former names
Biogen Idec INC. Idec Pharmaceuticals Corp
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
Cambridge
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
BIIB
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0000875045
EIN
33-0112644

Board of directors

Follow this board

Chief executives

Christopher Viehbacher · President and CEO
Dates unknown

Director election results

Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

10 of this board's directors also sit on 15 other boards.

Network of Biogen Inc.'s board connections Absci Corporation Absci Corporation Alexandria Real Estate Equities Inc. Alexandria Real Estate... Arch Capital Group Ltd. Arch Capital Group Ltd... Bioventus Inc. Bioventus Inc. Braveheart Bio Inc. Braveheart Bio Inc. Caris Life Sciences Inc. Caris Life Sciences In... Duke Energy Corporation (Holding Company) Duke Energy Corporatio... Dyne Therapeutics Inc. Dyne Therapeutics Inc. Exelixis Inc. Exelixis Inc. Fortress Biotech Inc. Fortress Biotech Inc. Illumina Inc. Illumina Inc. International Flavors & Fragrances Inc. International Flavors... MiMedx Group Inc MiMedx Group Inc Neurocrine Biosciences Inc. Neurocrine Biosciences... Verastem Inc. Verastem Inc. Brian S. Posner Brian S. Posner Caroline Dorsa Caroline Dorsa Christopher Viehbacher Christopher Viehbach... Eric K. Rowinsky Eric K. Rowinsky Jesus B. Mantas Jesus B. Mantas Lloyd Minor Lloyd Minor Maria C. Freire Maria C. Freire Menelas N. Pangalos Menelas N. Pangalos Stephen A. Sherwin Stephen A. Sherwin William A. Hawkins William A. Hawkins Biogen Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$585
1 purchase by 1 insider
Sold, last 12 months
$905,414
4 sales by 2 insiders
Date Insider Transaction Shares Price Value
Aug 4, 2026 Lloyd Minor Director Open-market sale −593 $200.96 $119,169
Aug 3, 2026 Lloyd Minor Director Open-market sale −593 $203.34 $120,581
Jun 9, 2026 William A. Hawkins Director Grant or award +1,505 — —
Jun 9, 2026 Stephen A. Sherwin Director Grant or award +1,505 — —
Jun 9, 2026 Eric K. Rowinsky Director Grant or award +1,505 — —
Jun 9, 2026 Jesus B. Mantas Director Grant or award +1,505 — —
Jun 9, 2026 Susan Langer Director Grant or award +1,505 — —
Jun 9, 2026 Monish D. Patolawala Director Grant or award +1,505 — —
Jun 9, 2026 Menelas N. Pangalos Director Option exercise +2,370 — —
Jun 9, 2026 Lloyd Minor Director Grant or award +1,505 — —
Jun 9, 2026 Maria C. Freire Director Grant or award +2,005 — —
Jun 9, 2026 Menelas N. Pangalos Director Grant or award +1,505 — —
May 1, 2026 Keeney Adam Officer (Head of Corporate Development) Option exercise +939 — —
May 1, 2026 Keeney Adam Officer (Head of Corporate Development) Shares withheld for tax −455 $187.06 $85,112
Apr 1, 2026 Godbout Sean Officer (Chief Accounting Officer) Option exercise +181 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.